Sunflower announced that the company plans to purchase 100% of the shares of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beide Pharmaceutical Co., Ltd. and raise supporting capital by issuing shares and paying cash, forming a major asset restructuring. Trading of the company's shares was suspended on September 8, 2025, and resumed trading on September 22. As of the announcement disclosure date, the audit, evaluation and due diligence work involved in this transaction is progressing in an orderly manner, and the company is continuing to communicate and negotiate with all relevant parties. The transaction still requires review and approval by the board of directors and shareholders' meetings, and can only be implemented after approval by the competent supervisory authority. There is uncertainty.

Sunflower announced that the company plans to purchase 100% of the shares of Zhangzhou Xipu Material Technology Co., Ltd. and 40% of Zhejiang Beide Pharmaceutical Co., Ltd. and raise supporting capital by issuing shares and paying cash, forming a major asset restructuring. Trading of the company's shares was suspended on September 8, 2025, and resumed trading on September 22. As of the announcement disclosure date, the audit, evaluation and due diligence work involved in this transaction is progressing in an orderly manner, and the company is continuing to communicate and negotiate with all relevant parties. The transaction still requires review and approval by the board of directors and shareholders' meetings, and can only be implemented after approval by the competent supervisory authority. There is uncertainty.